Plenary session, April 9th
Plenary session, April 9th, Palais de l’Europe, Menton
Presentations are available for viewing in PDF format but should not be used without authors’ permission
08.00 – Forewords (general): M. Meignan – A. Gallamini – C. Haioun 
08.30 – 09.30: New frontiers
Chairmen: A. Levis, L. Giovanella
08.30 – 09.00: L. Kostakoglu
- Has the interim PET retained its prognostic role in lymphoma?
09.00 – 09.30: Y. Kasamon
- How can we incorporate PET in clinical prospective trials (USA experience)?
09.30 – 11.45: Current studies with interim PET – Hodgkin lymphoma
Chairmen: A. Polliack, A. Biggi
Chairmen: N. Mounier, S. Bardet
09.30 – 10.00: Early HL
- M. André, J. Raemaekers, A. Versari: The H10 study
- J. Radford: The RAPID study
10.00 – 10.15: Coffee break
10.15 – 11.45: Advanced-stage HL
- P. Johnson: The RATHL study
- A. Gallamini: The GITIL HD0607 study
- E. Brusamolino: The IIL HD0801 study
- L. Chavdarova: Euronet Paediatric PHL-C1study
- O. Casasnovas, C. Fermé: The GELA study
- A. Engert: The GHSG HD18 study
- E. Dann: The Haifa study
- J.M. Zaucha: The Polish study
12.00 – 12.45: Round table
Is time for a European PET response-adapted protocol for DLBCL?
Chairmen: B. Coiffier (GELA), C. Haioun (GELA)
U. Vitolo (IIL) , M. Pfreundschuh (DNHLSG), G. Mikhaeel (MRC) , C. Haioun (GELA)
13.00 – 14.00: Coffee break
14.00 – 15.00: Open issues in interim PET
Chairmen: M. Federico, S. Barrington
14.00 – 14.30: L. Brepoels
- Interim PET (what can we learn from animal studies?) with emphasis on the effect of drugs
14.30 – 15.00: R. Hicks
- Interim PET in solid tumours
15.00 – 15.10: Coffee break
15.10 – 16.30: Current studies with interim PET – Non Hodgkin lymphoma
Chairmen: H. Tilly, T. van der Borght
Part 1: DLBCL
- C. Moskowitz: The MSKCC 01-142 study
- U. Dührsen: The PETAL study
- D. Caballero: The GELTAMO study
- O. Casasnovas, F. Morschhauser: The LNH07-3B study
- G. Mikhaeel: The UK-NCRI study
- L. Sehn: The BCCA study
- U. Vitolo: The IIL studies
- L. Ceriani: The Swiss experience
- M. Trneny: The PET-RIMCEB study
Part 2: Follicular lymphoma
- B. Cheson: The CALGB study
- M. Meignan: The PCR06002 study
16.30 – 17.30: International Validation Studies
Chairmen: B. Cheson, J. Seymour
16.30 – 16.45: A. Gallamini
- International validation Study in HL
16.45 – 17.00: C. Haioun, E. Itti
- International validation Study in DLBCL
17.00 – 17.30: Conclusions and next steps: M. Meignan